1/ My friend Jon Haidt Jonathan Haidt has written the MOST important article you can read today... "Why the Past 10 Years of American Life Have Been Uniquely Stupid––it's not just a phase"

In the past 5 years, I have conducted numerous job interviews. Those who got hired had 1 thing in common. They had one or more of these 13 UNIQUE traits:

Pipeline herding in drug development - In 2000, there were on avg 3 assets/target In 2022, there are on avg 7 assets/target (in oncology its 9 assets/target) nature.com/articles/d4157…

In May 2019, Dr. Richard Schilsky & I co-chaired the #AAADV19 Workshop Plenary Session "Decentralized #ClinicalTrials: The Future is Now." An incredible group of panelists from academia, industry, govt, & patient #advocacy 👇discussed the rationale, challenges, & opportunities of DCTs.

my dream molecule -350 MW -LogD ~2 -potent & selective -3 yrs from hit ID to candidate -under 10 mg PO daily dose -crystalline but not too crystalline -original, not a follower -hERG, CYP, PXR >100 uM -not genotoxic, phototoxic, etc. -good taste -loves me a LOT

Honored to accept the gavel from Dr. Winer & begin my term as ASCO Pres. I'm so excited to support ASCO & our members in their impt. work advancing cancer research & improving care for our pts through my presidential theme: “The Art & Science of Oncology: From Comfort to Cure”

Pricing austerity and regulatory conservatism hurt small companies disproportionally because of their higher cost of capital. Policy headwinds favor the big boys with big balance sheets.

I've been doing this awhile & I can say this: Nothing the FDA does/allows prior to seeing a full BLA/NDA data package is predictive of the final FDA decision. Not Fast Track. Not Orphan Designation. Not Accelerated Review. (Certainly) not allowing a rolling NDA/BLA. Not a SPA.

Talking to second time founders (especially v. successful ones), I've realized they tend to make the same mistakes. In fact, I made these myself in my brief attempt to start a second company after Scribd. The three most common ones:

When the Prince of Denmark declines to cut down his uncle Claudius from behind, while the fratricide is ineffectually praying, we are tempted to become impatient with Shakespeare's most charismatic protagonist. Reflection teaches us that we are wrong to so react; Hamlet is...

There’s a lesson for biopharma managers here, somehow.

I collect 'Sentences I wish I wrote.' Here are 7 of the best: 1. F Scott Fitzgerald, The Great Gatsby

A little self deprecation eases the pain. But I think we’ve lost our window with Francona. 2016 World Series game 7 vs Cubs. So close!

When we think of the World Trade Center, we think of September 11th. When we think of 9/11, we think about the first responders who showed up that day. …and when we remember what our police and firefighters did that day, we think of Jon Stewart, who fought tirelessly to get

Everyone in biotech right now is praying that E. Eric Tokat is on the verge of collapse tonight. 🙏😂

To all my colleagues, past and present. This is the joy I get from redlining your Word documents. Sorry.

I hope the second string for both teams gets some quality PT in the second half.

Reasonable financial incentives for pathology labs would be the best policy fix. It’s the most reliable predictor of new technology uptake in medicine.

More than 1 million people are dying each year from antibiotic resistance, considered a global health emergency. The pharma industry is doing little to respond. Thankfully academic labs, using A.I. and structure-based discovery, are kicking in. My summary Table of recent progress

If you don’t know what “cognitive biases” are, Kahneman will teach you….and make you realize you’ve exhibited them all